Background: Osteoporosis is a skeletal disease, which is characterized by low bone mineral density (BMD) and alterations in bone micro-architecture, that leads to bone fragility. Objectives: In this study, we had an aim to establish the expression of a decrease in bone density in postmenopausal women with diabetes and osteoporosis, and compare with expression of a decrease in bone density in postmenopausal women with osteoporosis and without diabetes, in order to evaluate and compare effect of bisphosphonate therapy in these two groups. Methods: The study was retrospective, clinical, performed in a two-year period and processed in 2019. With method of random sampling of hospitalized patients at the Clinic for Endocrinology, Diabetes and Metabolic Diseases or examined at the Endocrinology Counseling Center of the same clinic was used to select 25 menopausal women aged 46-70 years with osteoporosis and diabetes mellitus type 2, treated with insulin therapy more than two years. For the control group, 25 menopausal women aged 46-70 years, with osteoporosis and without type 2 diabetes were selected. Patients were monitored for a period of 6 months, before and after the introduction of bisphosphonate therapy (Fosamax tablets 1x70 mg per week). Results: There was no statistically significant difference in age and duration of menopause between groups. In the group of patients with diabetes there was no significant difference between BMI values at the beginning and at the end of the study, while in patients without diabetes there was an increase in BMI at the beginning and the end of study. The group of subjects with diabetes had not significantly lower values of T-score compared to the group of subjects without diabetes at the beginning of the study but had lower values of T-score for lumbar spine after 6 months of treatment of osteoporosis. At the end of the study there was no significant increase in the value of the T-score in both groups. Conclusion: There was no significant difference in the severity of osteoporosis in postmenopausal women with diabetes mellitus and postmenopausal women without diabetes, except after 6 months of osteoporosis treatment, when bone mineral density was lower in the group of patients with diabetes. There is a higher risk of osteoporosis in women with a longer duration of menopause, that is, the duration of menopause is directly related to osteoporosis.
osteoporosis, diabetes mellitus tip2, postmenopausal
Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity.
Ferrari F, Moretti A, Villa RF
Neural regeneration research. 2022; 17(2): 292-299
Assessment of structural brain changes in patients with type 2 diabetes mellitus using the MRI-based brain atrophy and lesion index.
Zhao H, Wang F, Luo GH, Lei H, Peng F, Ren QP, Chen W, Wu YF, Yin LC, Liu JC, Pan SN
Neural regeneration research. 2022; 17(3): 618-624
The Importance of Experimental Investigation of the Peripheral Oxytocin System.
Methods in molecular biology (Clifton, N.J.). 2022; 2384(): 1-27
Diabetes mellitus and Parkinson's disease: dangerous liaisons between insulin and dopamine.
De Iuliis A, Montinaro E, Fatati G, Plebani M, Colosimo C
Neural regeneration research. 2022; 17(3): 523-533
Methods to Analyze the Effect of Diet-Derived Metabolites on Endothelial Inflammation and Cell Surface Glycosaminoglycans.
Cutler BR, Chua JS, Balagurunathan K, Anandh Babu PV
Methods in molecular biology (Clifton, N.J.). 2022; 2303(): 469-476